DJIA 18,010.68 -115.44 -0.64%
NASDAQ 5,070.03 -27.95 -0.55%
S&P 500 2,107.39 -13.40 -0.63%
market minute promo

Gilead Sciences (NASDAQ: GILD)

112.27 -0.58 (-0.51%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

GILD $112.27 -0.51%
Company Photos
(Click to zoom)
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $113.15
Previous Close $112.85
Daily Range $111.85 - $113.37
52-Week Range $78.50 - $116.83
Market Cap $165.0B
P/E Ratio 12.85
Dividend (Yield) $1.72 (1.5%)
Ex-Dividend Date
Dividend Pay Date
06/12/15
06/29/15
Volume 11,329,998
Average Daily Volume 11,483,662
Current FY EPS $11.04

Sector

Healthcare

Industry

Drug Makers

Gilead Sciences (GILD) Description

Gilead Sciences created and sells the world’s top-selling HIV medications, Truvada and Atripla, and commands about 75% of the U.S. treatment market and more than 50% worldwide. Website: http://www.gilead.com/

News & Commentary Rss Feed

3 Best of Breed Biotech Stocks

These best of breed biotech stocks have bark and bite.

Pacira-FDA Meet for Exparel's Nerve Block Label Expansion - Analyst Blog

Is CVS Health (CVS) Worth Adding to Your Portfolio Now? - Analyst Blog

Does This Data Show 2015 Is Finally The Year To 'Sell In May?'

Strong Future Revenue And Earnings Growth Earn CVS Health A Bullish Thesis

Actavis' Viberzi Gets FDA Nod for Irritable Bowel Syndrome - Analyst Blog

Qiagen Launches Clinical Insight Bioinformatics Platform - Analyst Blog

How The Big Money Cashes In On Merck

Gilead Sciences Is Still Undervalued

Gilead's Sustainable Competitive Advantage

Gilead Sciences' long-term growth is being doubted by the Street because of the uncertainty surrounding the hep C market going forward. The biotech's top notch CEO John Martin, however, should be reason enough for investors to believe that company's best days lie ahead. Here's why.

See More GILD News...

GILD's Top Competitors

GILD $112.27 (-0.51%)
Current stock: GILD
AMGN $156.26 (-0.69%)
Current stock: AMGN
CELG $114.44 (-0.43%)
Current stock: CELG
$0.00 (0.00%)
Current stock: